Updates are available Correction dated 2026-08-03
Click to view Correction: https://doi.org/10.1038/s43018-026-01227-x
-
Authors
Bunse, Lukas https://orcid.org/0000-0002-4490-7574
Lindner, Katharina https://orcid.org/0000-0002-2735-3266
Wick, Antje
Freitag, Angelika
Lanz, Lisa-Marie
Edelmann, Dominic
Suwala, Abigail
Breckwoldt, Michael O.
Harting, Inga
Sahm, Felix https://orcid.org/0000-0001-5441-1962
Schlenk, Richard F. https://orcid.org/0000-0003-2215-2059
Schmitt, Anita
Schnell, Oliver
Hense, Jörg
Misch, Martin
Krex, Dietmar
Denk, Monika
Walz, Juliane https://orcid.org/0000-0001-6404-7391
Steinbach, Joachim P.
von Deimling, Andreas https://orcid.org/0000-0002-5863-540X
Schmitt, Michael https://orcid.org/0000-0002-1579-1509
Bunse, Theresa https://orcid.org/0000-0003-1834-4269
Tabatabai, Ghazaleh https://orcid.org/0000-0002-3542-8782
Bendszus, Martin
Poschke, Isabel
Wick, Wolfgang https://orcid.org/0000-0002-6171-634X
Platten, Michael https://orcid.org/0000-0002-4746-887X
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB1389)
Deutsche Forschungsgemeinschaft (SFB1389)
Deutsche Forschungsgemeinschaft (SFB1389)
Deutsche Forschungsgemeinschaft (SFB1389)
Deutsche Forschungsgemeinschaft (SFB1389)
Deutsche Forschungsgemeinschaft (SFB1389)
Deutsche Forschungsgemeinschaft (SFB1389)
Deutsche Forschungsgemeinschaft (SFB1389)
- License Information
-
More Information
Article History
Received: 30 October 2025
Accepted: 8 June 2026
First Online: 1 July 2026
Change Date: 3 August 2026
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s43018-026-01227-x
Ethics
Competing interests: F.S. is a cofounder and shareholder of Heidelberg Epignostix. D.K. has received honoraria for lectures, consultation or advisory board participation from Novocure and BrainLab. A.v.D. holds patents EP15158660 (‘DNA methylation-based method for classifying tumor species’), EP09015511 (‘Means and methods for diagnosing cancer using an antibody that specifically binds to BRAF-V600E’) and EP09015511 (‘Methods for diagnosis and prognosis of a brain tumor; IDH H09 antibody’), receives royalties from Dianova for IDHR132H AB H09 and Roche for BRAF-V600E AB VE1 and is a cofounder and owner of the company Heidelberg Epignostix. T.B., W.W. and M.P. are inventors and patent holders for EP2800580B1 (‘Peptides for use in treating or diagnosing IDH1-R132H-positive cancers’). G.T. has served on advisory boards (Bayer, Boehringer Ingelheim, CureVac, Miltenyi Biomedicine, Novocure and Servier), as a consultant (Bayer, Boehringer Ingelheim and CureVac), as a steering committee member in noninterventional trials (Bayer and Novocure) and as a speaker (Novocure and Servier). M.P. is the founder of Tcelltech.
